8-K
NASDAQ false 0001661181 0001661181 2023-06-13 2023-06-13

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): June 13, 2023

 

 

ORGANOGENESIS HOLDINGS INC.

(Exact Name of Registrant as specified in its charter)

 

 

 

Delaware   001-37906   98-1329150

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

85 Dan Road

Canton, MA

    02021
(Address of principal executive offices)     (Zip Code)

(781) 575-0775

(Registrant’s telephone number, including area code)

Not Applicable

(Registrant’s name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange

on which registered

Class A Common Stock, $0.0001 par value   ORGO   Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 


Item 5.07.

Submission of Matters to a Vote of Security Holders.

We held our 2023 Annual Meeting of Stockholders on June 13, 2023, at which three proposals were submitted to, and approved by, our stockholders. The holders of 101,816,504 shares of our Class A common stock were present or represented by proxy at the meeting. The proposals are described in detail in our definitive proxy statement for the 2023 Annual Meeting filed with the Securities and Exchange Commission on May 1, 2023. The final results for the votes for each proposal are set forth below.

At the annual meeting, each of Alan A. Ades, Robert Ades, Michael J. Driscoll, Prathyusha Duraibabu, David Erani, Jon Giacomin, Gary S. Gillheeney, Sr., Michele Korfin, Arthur S. Leibowitz, Glenn H. Nussdorf and Gilberto Quintero was elected as a Director of the Company, to serve until the next Annual Meeting of Stockholders and until their successors are elected and qualified. The votes cast in the election of the directors were as follows:

 

Nominee

   Votes For    Votes Withheld    Broker
Non-Votes

Alan A. Ades

   61,627,518    3,823,463    36,365,523

Robert Ades

   61,626,993    3,823,988    36,365,523

Michael J. Driscoll

   62,439,161    3,011,820    36,365,523

Prathyusha Duraibabu

   63,265,527    2,185,454    36,365,523

David Erani

   61,703,819    3,747,162    36,365,523

Jon Giacomin

   47,474,289    17,976,692    36,365,523

Gary S. Gillheeney, Sr.

   64,607,644    843,337    36,365,523

Michele Korfin

   65,067,741    383,240    36,365,523

Arthur S. Leibowitz

   45,170,021    20,280,960    36,365,523

Glenn H. Nussdorf

   42,138,802    23,312,179    36,365,523

Gilberto Quintero

   64,990,594    460,387    36,365,523

At the annual meeting, our stockholders also approved, on an advisory basis, the compensation paid to the Company’s named executive officers. The votes cast on this proposal were as follows:

 

Proposal

   Votes For    Votes Against    Abstentions    Broker
Non-Votes

To approve, on an advisory basis, the compensation paid to the Company’s named executive officers.

   51,710,250    13,676,178    64,553    36,365,523

At the annual meeting, our stockholders also approved the proposal to ratify the appointment of RSM US LLP as our independent registered public accounting firm for our fiscal year ending on December 31, 2023. The votes cast on this proposal were as follows:

 

Proposal

   Votes For    Votes Against    Abstentions    Broker
Non-Votes

To ratify the appointment of RSM US LLP as the Company’s independent registered public accounting firm for fiscal year 2023

   101,491,715    238,798    85,991    0

 

2


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Organogenesis Holdings Inc.
By:  

/s/ Lori Freedman

Name:   Lori Freedman
Title:   Chief Administrative and Legal Officer

Date: June 16, 2023